Johnson & Johnson Newsroom

ChatGPT Stock Advice: Johnson & Johnson (JNJ) Among Top Stock Recommendations

Yahoo Finance05:12 ET

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Benzinga23:04 ET

Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

Benzinga16:13 ET

Top Midday Stories: Trump Vows 100% Tariff on Foreign-Made Films; Buffett to Step Down As Berkshire CEO

MT Newswires12:19 ET

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

BenzingaMay 5 11:43 ET

Market Chatter: India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs

MT NewswiresMay 5 10:52 ET

Was Jim Cramer Right About Johnson & Johnson (JNJ)?

Yahoo FinanceMay 5 09:29 ET

Teva, Alvotech Get FDA Nod for Johnson & Johnson Biosimilar

Seeking AlphaMay 5 09:27 ET

Johnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis

BenzingaMay 5 08:13 ET

Express News | Tremfya® (Guselkumab) Positioned to Become the First and Only Il-23 Inhibitor to Offer Subcutaneous Induction in Ulcerative Colitis as Demonstrated in New Data Through 24 Weeks

ReutersMay 5 08:05 ET

Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study

MT NewswiresMay 5 04:09 ET

Johnson & Johnson 'S New "Oncology Care Index" Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice

Johnson & JohnsonMay 5 00:00 ET

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

Barron'sMay 4 00:05 ET

Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two

Seeking AlphaMay 2 15:00 ET

RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181

Moomoo NewsMay 2 07:31 ET · Ratings

Goldman Sachs Adjusts Price Target on Johnson & Johnson to $176 From $172, Maintains Buy Rating

MT NewswiresMay 2 07:12 ET · Ratings

SA Charts: How U.S. Manufacturing Jobs Have Declined Since the 1980s

Seeking AlphaMay 2 06:43 ET

Express News | Jnj-Backed Histosonics Is Pursuing a Sale After Fielding Takeover Bids, Seeking a Valuation of More Than $2.5Bn - FT

ReutersMay 2 00:04 ET

8 Health Care Stocks Whale Activity In Today's Session

BenzingaMay 1 13:35 ET

Johnson & Johnson (JNJ.US) has received FDA approval for a potential blockbuster therapy.

Zhitong Finance APP learned that Johnson & Johnson (JNJ.US) announced that the USA FDA has approved the market launch of its antibody therapy Imaavy (nipocalimab).

Zhitong FinanceApr 30 21:48 ET